Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program-Reference-Cited by-同舟云学术

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program

Published:2016-02-24 Issue:8 Volume:122 Page:1228-1237
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Drilon Alexander¹²,Eaton Anne A.¹,Schindler Katja³,Gounder Mrinal M.¹²,Spriggs David R.¹²,Harris Pamela⁴,Ivy S. Percy⁴,Iasonos Alexia¹,Lacouture Mario E.¹,Hyman David M.¹²

Affiliation:

1. Department of Medicine; Memorial Sloan Kettering Cancer Center; New York New York

2. Department of Medicine; Weill Cornell Medical College; New York New York

3. Dermatology Department; Medical University of Vienna; Vienna Austria

4. Cancer Therapeutics and Evaluation Program, National Cancer Institute; Bethesda Maryland

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29918/fullpdf

Reference27 articles.

1. Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996;Arbuck;Ann Oncol,1996

2. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics;LoRusso;Clin Cancer Res,2010

3. Dose escalation methods in phase I cancer clinical trials;Tourneau;J Natl Cancer Inst,2009

4. Phase I trial design: are new methodologies being put into practice?;Dent;Ann Oncol,1996

5. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life;Nardone;J Drugs Dermatol,2012

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of anticancer therapy-related dermatologic adverse events: Insights from Food and Drug Administration's Adverse Event Reporting System dataset;Journal of the American Academy of Dermatology;2024-07

2. NECOM Skincare Algorithm for Patients With Cancer and Survivors;J DRUGS DERMATOL;2023

3. Evaluation of chemotherapy‐induced cutaneous side effects in cancer patients;International Journal of Dermatology;2022-07-22

4. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆;Annals of Oncology;2021-02

5. Adverse Cutaneous Reactions to Chemotherapeutic Agents;Hospital-Based Dermatopathology;2020